Phreesia ROE 2019-2025 | PHR
Current and historical return on equity (ROE) values for Phreesia (PHR) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Phreesia ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-04-30 | $-0.04B | $0.28B | -15.95% |
| 2025-01-31 | $-0.06B | $0.27B | -22.66% |
| 2024-10-31 | $-0.08B | $0.26B | -32.87% |
| 2024-07-31 | $-0.10B | $0.25B | -39.61% |
| 2024-04-30 | $-0.12B | $0.25B | -47.24% |
| 2024-01-31 | $-0.14B | $0.25B | -53.75% |
| 2023-10-31 | $-0.15B | $0.27B | -54.51% |
| 2023-07-31 | $-0.15B | $0.25B | -54.69% |
| 2023-04-30 | $-0.16B | $0.26B | -53.44% |
| 2023-01-31 | $-0.18B | $0.29B | -52.66% |
| 2022-10-31 | $-0.18B | $0.32B | -50.20% |
| 2022-07-31 | $-0.18B | $0.35B | -44.89% |
| 2022-04-30 | $-0.16B | $0.38B | -36.03% |
| 2022-01-31 | $-0.12B | $0.42B | -25.09% |
| 2021-10-31 | $-0.08B | $0.46B | -18.47% |
| 2021-07-31 | $-0.05B | $0.49B | -13.13% |
| 2021-04-30 | $-0.03B | $0.50B | -11.29% |
| 2021-01-31 | $-0.03B | $0.26B | -14.77% |
| 2020-10-31 | $-0.02B | $0.27B | -16.14% |
| 2020-07-31 | $-0.02B | $0.10B | -17.91% |
| 2020-04-30 | $-0.08B | $0.10B | -81.57% |
| 2020-01-31 | $-0.09B | $0.10B | -119.87% |
| 2019-07-31 | $-0.10B | $0.10B | -384.47% |
| 2019-04-30 | $-0.04B | $0.00B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $1.648B | $0.420B |
| Phreesia Inc. provides a patient intake management platform. The company's SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care. Phreesia Inc. is based in New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.412B | 59.05 |
| Tempus AI (TEM) | United States | $12.731B | 0.00 |
| Doximity (DOCS) | United States | $12.055B | 53.63 |
| Hims & Hers Health (HIMS) | United States | $9.805B | 80.33 |
| IRhythm Technologies (IRTC) | United States | $5.243B | 0.00 |
| Hinge Health (HNGE) | United States | $4.466B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.752B | 40.46 |
| Privia Health (PRVA) | United States | $2.596B | 192.27 |
| Heartflow (HTFL) | $2.379B | 0.00 | |
| Enovis (ENOV) | United States | $1.715B | 9.06 |
| 10x Genomics (TXG) | United States | $1.663B | 0.00 |
| Omnicell (OMCL) | United States | $1.458B | 28.10 |
| Schrodinger (SDGR) | United States | $1.425B | 0.00 |
| Azenta (AZTA) | United States | $1.365B | 59.54 |
| Clover Health Investments (CLOV) | United States | $1.302B | 0.00 |
| Claritev (CTEV) | United States | $1.088B | 0.00 |
| Evolent Health (EVH) | United States | $1.052B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.654B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.568B | 0.00 |
| Veradigm (MDRX) | United States | $0.531B | 0.00 |
| Standard BioTools (LAB) | United States | $0.470B | 0.00 |
| Talkspace (TALK) | United States | $0.430B | 128.50 |
| Butterfly Network (BFLY) | United States | $0.355B | 0.00 |
| Carlsmed (CARL) | United States | $0.320B | 0.00 |
| TruBridge (TBRG) | United States | $0.291B | 51.03 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.242B | 0.00 |
| Outset Medical (OM) | United States | $0.237B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.216B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.205B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.192B | 0.00 |
| CapsoVision (CV) | United States | $0.184B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.139B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.133B | 0.00 |
| CareCloud (CCLD) | United States | $0.112B | 5.08 |
| American Well (AMWL) | United States | $0.111B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.077B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.072B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| Pulmonx (LUNG) | United States | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.053B | 0.00 |
| HeartBeam (BEAT) | United States | $0.039B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.022B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.012B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| HeartSciences (HSCS) | United States | $0.009B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |